Pharmafile Logo
Pharmafocus logo
Advanced Search

Research and Development

Showing 15 posts of 9596 posts found.

patrick_chinnery

Professor Patrick Chinnery named as Clinical Director of MRC

February 26, 2019 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing

Professor Patrick Chinnery has been appointed to the role of Clinical Director at the Medical Research Council (MRC) the non-departmental …
Appointment
pharmafocus_march_2019_cover

Read the March 2019 issue of Pharmafocus online now!

February 26, 2019 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Cancer, Drug pricing, HIV, Trump, WHO, brexit, depression, mental health, pharmacovigilance, rare disease

Just one month to go until Brexit here in the UK, and it’s still all to play for. After months …
News

Living with melanoma after surgery

February 25, 2019 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Cancer, melanoma, patient experience, pharma

Dr Elizabeth Walmsley was left lost when she received her melanoma diagnosis. Thankfully, through perseverance and the advice of friends …
Feature
4420456374_64a3d7e6aa

Top Ten most popular articles on Pharmafile.com this week

February 22, 2019 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AstraZeneca, Cancer, China, MedImmune, Xeljanz, asthma, diabetes, keytruda, osteoarthritis, pharma, rare disease

Happy Friday! With the weekend within reach, check out our run-down of the top ten most popular articles on Pharmafile.com …
News
img_4190-e1376666350337-web

MHRA warns of congenital malformation risk of neo-mercazole during pregnancy

February 22, 2019 Medical Communications, Research and Development MHRA, neo-mercazole, pharma

UK drug watchdog The Medicines and Healthcare products Regulatory Agency (MHRA) has warned of the potential side-effects of Neo-mercazole (carbimazole) …
News

FDA halts Xencor’s acute myeloid leukaemia trial following two patient deaths

February 21, 2019 Research and Development Cancer, FDA, Xencor, leukaemia, pharma

Cancer biopharma firm Xencor has revealed it is to place a hold on its ongoing Phase 1 trial of XmAb14045, …
News

Pfizer overhauls Xeljanz study over concerns of increased risk of pulmonary embolism and death

February 21, 2019 Research and Development Pfizer, Xeljanz, pharma, rheumatoid arthritis

Pfizer is set to overhaul the dosing groups in its ongoing study of Xeljanz (tofacitinib) after an evaluation from a …
News
shutterstock_159488225

Intercept’s NASH liver fibrosis drug shows promise at Phase 3

February 20, 2019 Research and Development Intercept Pharmaceuticals, nash, non-alcoholic steatohepatitis, ocaliva, pharma

Intercept Pharmaceuticals has publicised promising new data on the efficacy of Ocaliva (obeticholic acid) in the treatment of liver fibrosis …
News
francesa

FDA approves Indian firm Alembic’s generic of Teva’s Diamox

February 20, 2019 Research and Development ANDA, Alembic, Gujurat, US FDA, diamox, generics

The US FDA has approved Guajarati firm Alembic Pharmaceuticals generic version of Teva’s Acetazolamide sold under the brand name Diamox, …
News

Pfizer and Eli Lilly’s chronic low back pain (CLBP) treatment meets primary endpoint in Phase 3 trial

February 20, 2019 Research and Development

US firms Pfizer and Eli Lilly have said that NGF inhibitor tanezumab met its primary endpoint in a phase 3 …
News
european_commission_web_5

Poland and Slovenia included in US-EU mutual recognition agreement

February 20, 2019 Research and Development EU, GMP, Poland, Slovenia, USA, mutual recognition

Poland and Slovenia have been deemed capable of carrying out Good Manufacturing Practice (GMP) inspections at an equivalent level to …
News
merckwindow_web

Keytruda falls short at Phase 3 in advanced liver cancer

February 20, 2019 Research and Development Cancer, MSD, keytruda, liver cancer, pharma

MSD has revealed new Phase 3 data which indicates that its blockbuster immunotherapy Keytruda (pembrolizumab), in combination with best supportive …
News
shutterstock_244903099

“Game-changing” osteoarthritis drug receives £675k funding from Innovate UK

February 19, 2019 Manufacturing and Production, Research and Development AKL Research and Development, Innovate UK, osteoarthritis, pharma

A novel and potentially “game-changing” oral therapy for the treatment of osteoarthritis (OA) has received a £675,000 cash injection from …
News
screen_shot_2019-01-29_at_15

Beating the flu

February 18, 2019 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing flu, influenza, pharma, seqirus

On 14 January, the European Commission issued marketing approval for Flucelvax Tetra, the first cell-based, quadrivalent influenza vaccine. Pharmafocus spoke …
Feature

Astellas’ Xtandi “significantly improves” progression-free survival in advanced hormone-sensitive prostate cancer

February 18, 2019 Research and Development, Sales and Marketing Astellas, Cancer, Xtandi, pharma, prostate cancer

Japanese pharma firm Astellas has lifted the curtain on new data for its androgen receptor signalling inhibitor Xtandi (enzalutamide), when …
News
The Gateway to Local Adoption Series

Latest content

Rhythm AI’s STAR Apollo system receives FDA clearance for atrial fibrillation

February 12, 2026

iOrganBio appoints Karol Jarzabek as Chief Operating Officer

February 12, 2026

Ensera Design expands UK leadership team with new senior appointments

February 11, 2026

Infinitopes announces $15.4m in additional seed funding to advance cancer vaccine

February 11, 2026

Angelini Pharma appoints Roberto Scrivo as Chief of External Affairs, Communication and Sustainability Officer

February 10, 2026